Budget Impact of Chosing Rebif® as the Interferon of Choice for the Treatment of Relapsing-Remitting Multiple Sclerosis In the Brazilin Public Healthcare System
Abstract
Authors
R.K. Fujii S. Wong M. Junqueira
R.K. Fujii S. Wong M. Junqueira
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now